Se-cure Pharmaceuticals & Cosmetics, Ltd. – Trademark Portfolio

Entity Type: 03

Se-cure Pharmaceuticals & Cosmetics, Ltd. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 1 trademark is registered. Notable registered marks include FEMARELLE. The owner is based in Yavne 81103.

1 Hayarmuch Street

Yavne 81103 , IL

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

FEMARELLE
FEMARELLE
Registered 2003
TOFUPILL
TOFUPILL
Abandoned 2001

Trademark Classifications

Se-cure Pharmaceuticals & Cosmetics, Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Se-cure Pharmaceuticals & Cosmetics, Ltd. have?

Se-cure Pharmaceuticals & Cosmetics, Ltd. has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned.

What trademark classes does Se-cure Pharmaceuticals & Cosmetics, Ltd. file in?

Se-cure Pharmaceuticals & Cosmetics, Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Se-cure Pharmaceuticals & Cosmetics, Ltd.'s most well-known trademarks?

Se-cure Pharmaceuticals & Cosmetics, Ltd.'s registered trademark portfolio includes well-known marks such as FEMARELLE. These are among 1 currently registered trademark in the portfolio.

What is Se-cure Pharmaceuticals & Cosmetics, Ltd.'s trademark registration success rate?

Se-cure Pharmaceuticals & Cosmetics, Ltd. has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.